Abris Invests in ITP S.A., One of the Fastest Growing Companies on the Aesthetic Medicine Market

WARSAW, Poland, July 18, 2018 /PRNewswire/ --

On 13^th July 2018, Nept Holdings sarl, a subsidiary of Abris CEE Mid-Market Fund III LP, a PE fund managed by Abris Capital Partners Ltd., acquired a strategic stake in ITP S.A., a Polish company which sells its innovative aesthetic medicine products in more than 45 countries.

     (Logo: http://mma.prnewswire.com/media/555610/Abris_Capital_Partners_Logo.jpg )

ITP S.A. is a dynamically growing company operating on the aesthetic medicine, beauty, fitness and wellness markets. It owns the Neauvia brand - a new generation of hyaluronic acid dermal fillers and a line of professional cosmeceuticals currently sold in more than 45 countries around the world. The company specialises in selecting the best technologies and global brands on the aesthetic medicine, medical devices and wellness equipment markets and then sells them successfully in Poland and worldwide. ITP S.A.'s rapid development is also the result of its business strategy, based upon a unique and holistic approach to the client, the development of long-term relationships with partners and full support at all stages of cooperation.

This is Abris' fifth investment from the EUR 500 million secured in autumn 2017 from international investors to support interesting business projects in Poland and Central and Eastern Europe.

"We believe that a Polish company performing so well on the very demanding luxury product market of aesthetic medicine is a real diamond. At Abris, we like to support ambitious projects delivered with passion by their founders. This is why we chose ITP SA. We intend to support the company not only financially, but also, and perhaps above all, with our know-how and help make it an international star on the aesthetic medicine market," said Pawe? Giery?ski, Managing Partner at Abris Capital Partners.

2015 was a landmark year for ITP with the acquisition of MatexLab, the Swiss producer and distributor of hyaluronic fillers. This led to the creation of the third, vitally important revenue stream and the start of the company's dynamic international expansion. The dermal fillers are produced at the company's laboratory in Italy. MatexLab invests heavily in its own R&D, working on new product development and innovative medical applications.

"We are currently focused primarily on further development of our innovative Neauvia dermal fillers which were created by our in-house R&D department. We would like to focus even more on international expansion. We are already well-placed in Central and Eastern Europe and the Middle East, and our products are distributed on five continents. Now it's time to expand into China and the USA - the largest markets in the world. In China, we have already started the registration procedure, while in the USA we plan to submit the necessary paperwork before the year end. In order to do all this, we need a trusted partner who, in addition to financing further growth, can guarantee us professional support with the intricacies of our international expansion. This is why we chose Abris Capital Partners," said Gabriele Drigo, ITP S.A. CEO and Management Board Chairman.